WO2001039760A3 - Method of treating batten disease - Google Patents

Method of treating batten disease Download PDF

Info

Publication number
WO2001039760A3
WO2001039760A3 PCT/US2000/029913 US0029913W WO0139760A3 WO 2001039760 A3 WO2001039760 A3 WO 2001039760A3 US 0029913 W US0029913 W US 0029913W WO 0139760 A3 WO0139760 A3 WO 0139760A3
Authority
WO
WIPO (PCT)
Prior art keywords
batten disease
subject
treating
active agent
flupirtine
Prior art date
Application number
PCT/US2000/029913
Other languages
French (fr)
Other versions
WO2001039760A2 (en
Inventor
Rose-Mary N Boustany
Original Assignee
Univ Duke
Boustany Rose Mary N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Boustany Rose Mary N filed Critical Univ Duke
Priority to US10/148,859 priority Critical patent/US6821995B1/en
Priority to AU13539/01A priority patent/AU1353901A/en
Publication of WO2001039760A2 publication Critical patent/WO2001039760A2/en
Publication of WO2001039760A3 publication Critical patent/WO2001039760A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating Batten disease in a subject in need thereof comprises administering to said subject an active agent selected from the group consisting of flupirtine and the pharmaceutically acceptable salts thereof in an amount effective to treat Batten disease in that subject. The administering step is preferably an oral administering step, and the active agent is preferably flupirtine maleate. The use of such active agents for the preparation of a medicament for the treatment of Batten disease is also disclosed.
PCT/US2000/029913 1999-12-01 2000-10-30 Method of treating batten disease WO2001039760A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/148,859 US6821995B1 (en) 1999-12-01 2000-10-30 Method of treating batten disease
AU13539/01A AU1353901A (en) 1999-12-01 2000-10-30 Method of treating batten disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16828799P 1999-12-01 1999-12-01
US60/168,287 1999-12-01

Publications (2)

Publication Number Publication Date
WO2001039760A2 WO2001039760A2 (en) 2001-06-07
WO2001039760A3 true WO2001039760A3 (en) 2002-01-17

Family

ID=22610875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029913 WO2001039760A2 (en) 1999-12-01 2000-10-30 Method of treating batten disease

Country Status (2)

Country Link
AU (1) AU1353901A (en)
WO (1) WO2001039760A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
DE102017007385A1 (en) 2017-08-02 2019-02-07 Christoph Hoock Maleate-free solid dosage forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005175A1 (en) * 1993-08-17 1995-02-23 Asta Medica Aktiengesellschaft The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
WO1997049398A1 (en) * 1996-06-27 1997-12-31 Asta Medica Aktiengesellschaft Use of flupirtine to prevent cell damage by apoptosis and necrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005175A1 (en) * 1993-08-17 1995-02-23 Asta Medica Aktiengesellschaft The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
WO1997049398A1 (en) * 1996-06-27 1997-12-31 Asta Medica Aktiengesellschaft Use of flupirtine to prevent cell damage by apoptosis and necrosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LANE STEVEN C ET AL: "Apoptosis as the mechanism of neurodegeneration in Batten's disease.", JOURNAL OF NEUROCHEMISTRY, vol. 67, no. 2, 1996, pages 677 - 683, XP001012419, ISSN: 0022-3042 *
MULLER WERNER E G ET AL: "Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: Prevention of amyloid-induced glutathione depletion.", JOURNAL OF NEUROCHEMISTRY, vol. 68, no. 6, 1997, pages 2371 - 2377, XP001012408, ISSN: 0022-3042 *
PEROVIC S ET AL: "FLUPIRTINE INCREASES THE LEVELS OF GLUTATHIONE AND BCL-2 IN HNT (HUMAN NTERA/D1) NEURONS: MODE OF ACTION OF THE DRUG-MEDIATED ANTI-APOPTOTIC EFFECT", EUROPEAN JOURNAL OF PHARMACOLOGY,NL,AMSTERDAM, vol. 317, no. 1, 12 December 1996 (1996-12-12), pages 157 - 164, XP000673257, ISSN: 0014-2999 *
PEROVIC SANJA ET AL: "Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases.", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 101, no. 1-2, 16 March 1998 (1998-03-16), pages 1 - 19, XP002940559, ISSN: 0047-6374 *
PURANAM K ET AL: "Upregulation of Bcl-2 and elevation of ceramide in Batten disease.", NEUROPEDIATRICS, vol. 28, no. 1, 1997, pages 37 - 41, XP001012411, ISSN: 0174-304X *
PURANAM KASTURI L ET AL: "CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide.", MOLECULAR GENETICS AND METABOLISM, vol. 66, no. 4, April 1999 (1999-04-01), pages 294 - 308, XP002940558, ISSN: 1096-7192 *

Also Published As

Publication number Publication date
AU1353901A (en) 2001-06-12
WO2001039760A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
CA2366865A1 (en) Flupirtine in the treatment of fibromyalgia and related conditions
HK1076379A1 (en) Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis
WO2001091736A3 (en) Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
YU48559B (en) Pharmaceutical formulation for treating nicotine addiction
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
JP2004537500A5 (en)
NZ507203A (en) Use of dexmedetomidine for ICU sedation
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
NO20042758L (en) Procedure for treating a patient requiring analgesia.
SE9902597D0 (en) New use
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2001039760A3 (en) Method of treating batten disease
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2001001995A3 (en) Method for treatment of asthma syndrome
CA2403674A1 (en) The use of t3 for treating congestive heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10148859

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase